<DOC>
	<DOCNO>NCT00426543</DOCNO>
	<brief_summary>The primary purpose study determine whether B-cell depletion Rituximab effect oral , ocular general disease manifestation patient primary Sjögren´s syndrome , , effect symptom oral ocular dryness , improvement glandular function beneficial effect general symptom fatigue . The secondary purpose study investigate underlying autoimmune pathophysiological mechanism Sjögren´s syndrome .</brief_summary>
	<brief_title>Effect B-cell Depletion Patients With Primary Sjögren 's Syndrome</brief_title>
	<detailed_description>The trial design double-blind parallel comparison 2 infusion 1 g Rituximab solvent ( saline ) give two week apart , 22 patient diagnosis primary Sjögren 's syndrome base current American-European consensus classification criterion . The patient follow Department Oral Medicine , Clinical Oral Physiology , Oral Pathology &amp; Anatomy , University Copenhagen , Department Rheumatology , Rigshospitalet Department Ophthalmology , Rigshospitalet . The primary endpoint clinical response delineate least 50 % improvement score . With provision occur item least 60 % treated patient compare 1 % control patient , power 80 % double sided significance level 5 % find 20 patients.The patient follow within study 6 month Rituximab . The study allow first real dynamic appraisal immunologic pathophysiology Sjögren 's syndrome . Hence attempt make determine best possible level Rituximab influence possibly reset autoimmunity whole body particularly local level salivary gland . Also basal transport mechanism salivary secretion must necessarily perturb Sjögren 's syndrome scrutinize employ best available technique . Every possible effort envisage priory , monitor , decisive mechanism make . In particular include repetitive biopsy parotid gland , allow combine functional structural data reduce much possible random variability crucial quantity . Also allow first time assess relative combine utility obtain biopsy parotid labial salivary gland . Roche A/S provide investigational medicine , study initiate entirely control investigator .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Fatigue</mesh_term>
	<mesh_term>Xerostomia</mesh_term>
	<mesh_term>Sjogren 's Syndrome</mesh_term>
	<mesh_term>Keratoconjunctivitis</mesh_term>
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Female patient fulfil current AmericanEuropean consensus classification criterion . Fertileage female patient must use safe anticonceptional method pill , minipills , intrauterine spiral . The fertileage female include study must get pregnant least 12 month last treatment Rituximab . Pregnancy lactation . Fertileage female use safe anticonceptional method . Patients systemic treatment cytostatics . Patients previously treat Rituximab . Patient active infection require antibiotic treatment .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Clinical trial</keyword>
	<keyword>Intervention study</keyword>
	<keyword>Double-blind randomise control study</keyword>
</DOC>